Evolus

Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November 2012 and is headquartered in Newport Beach, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Evolus reports robust Q4 earnings, eyes international expansion and profitability

Evolus' Q4 2022 performance exceeded expectations, driven by strong revenue growth and customer acquisition.
The company's strategic focus on market share gains, international expansion, and profitability sets a positive trajectory.
Challenges from new competition and market dynamics require strategic responses to maintain leadership.
Opportunities in international expansion, corporate development, and market growth position Evolus for future success.

Evolus secures strategic partnership for growth in dermal filler market

Evolus' strong Q1 performance and strategic partnership with Symatese position the company for significant growth in the dermal filler market.
While facing challenges in safety comparisons and patient demographics, Evolus has opportunities to leverage its unique manufacturing process and upcoming data releases for market advantage.
Overall, Evolus is well-funded, poised for profitability, and focused on differentiating its product line for long-term success.

Evolus (EOLS) exceeds Q2 sales targets, eyes international expansion

Evolus (EOLS) delivered a strong performance in Q2, with accelerated sales growth, efficient cost management, and a focus on profitability, positioning the company for future success.
While facing challenges in market penetration and profitability, Evolus's strategic strengths in customer acquisition, innovation, and financial discipline provide a solid foundation for growth.
With opportunities for revenue expansion, international market growth, and disruptive product launches, Evolus is poised to capitalize on its strengths and address key challenges to drive long-term value for investors.

Evolus (EOLS) achieves record revenue and profitability, eyes global expansion

Evolus (EOLS) delivered a stellar performance in Q3 2023, with record revenue, strong financials, and promising R&D outcomes, positioning the company for continued growth and profitability.
The company's strategic strengths lie in market expansion, brand loyalty, and a clear long-term vision, supported by confidence in achieving ambitious revenue targets and product innovation.
While challenges in market competition and resource optimization persist, Evolus has opportunities in market segments, international expansion, and industry visibility to drive future growth.

Evolus surpasses revenue targets, eyes $700 million goal by 2028

Evolus delivered strong financial performance in Q4 2023, exceeding revenue expectations and achieving profitability. With a strategic focus on market expansion, product differentiation, and customer engagement, the company aims to reach a revenue target of $700 million by 2028.

Evolus reports robust Q1 growth, eyes $700M revenue target by 2028

Evolus demonstrated strong financial performance and market expansion in Q1 2024, with a focus on operational efficiency and customer engagement. The company's strategic goals include achieving profitability by year-end and targeting substantial revenue growth by 2028.
While facing challenges in market dynamics and profitability targets, Evolus remains optimistic about its competitive position and growth prospects. Opportunities lie in leveraging loyalty programs, expanding internationally, and launching new product lines to drive future success.

Evolus reports profitable Q2, eyes global expansion and new products

Evolus demonstrated strong performance in Q2 2024, achieving profitability and revenue growth.
The company's focus on innovation, international expansion, and financial management positions it for future success.
Challenges lie in maintaining growth momentum, executing expansion plans, and managing costs effectively.
Opportunities include capitalizing on market demand, global expansion, product innovation, and financial optimization.

Evolus reports strong Q3 growth, eyes $700M revenue target

Evolus showcased robust growth and strategic initiatives in Q3 2024, aiming for significant revenue targets by 2028. While facing revenue challenges and market competition, the company's strengths in product innovation and market expansion offer opportunities for sustained growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus announces that members of its management team will be participating in the H.C. Wainwright 24th Annual Global Investment Conference.

Evolus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Newly Published Post Hoc Analysis Evaluates Efficacy of Evolus' Jeuveau® in Adult Males Compared to BOTOX®

Newly Published Post Hoc Analysis Evaluates Efficacy of Jeuveau® in Adult Males Compared to BOTOX®

Evolus, Inc. (NASDAQ:EOLS ) Q2 2022 Earnings Conference Call August 1, 2022 9:00 AM ET Company Participants David Erickson - Vice President, Investor Relations David Moatazedi - President and Chief Executive Officer Rui Avelar - Chief Medical Officer and Head of Research and Development Conference Call Participants Louise Chen - Cantor Fitzgerald Annabel Samimy - Stifel Marc Goodman - SVB Greg Fraser - Truist Securities Serge Belanger - Needham and Company Douglas Tsao - H.C. Wainwright Uy Ear - Mizuho Operator Greetings.

Evolus, Inc. (EOLS) CEO David Moatazedi on Q2 2022 Results - Earnings Call Transcript

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus reports financial results for the second quarter ended June 30, 2022 and provides a business update.

Evolus Reports Second Quarter 2022 Results and Provides Business Update

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus announces it will report its second quarter 2022 financial results and provide a business update on Tuesday, August 2, 2022, before market.

Evolus to Report Second Quarter 2022 Results and Provide Business Update

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus launches new consumer engagement campaign offering Jeuveau discounts and challenging consumers to "Switch Your Tox and Love Evolus Forever."

Evolus Launches New Campaign Inspiring Consumers to “Switch Your Tox and Love Evolus Forever”

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus has completed patient enrollment in its clinical study evaluating an “extra-strength” dose for extended duration of Jeuveau®.

Evolus Successfully Completes Patient Enrollment in Phase II Clinical Study Evaluating “Extra-Strength” Dose of Jeuveau®

The mean of analysts' price targets for Evolus, Inc. (EOLS) points to a 28.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does Evolus, Inc. (EOLS) Have the Potential to Rally 28% as Wall Street Analysts Expect?

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus announced that Dermatologic Surgery published a post hoc analysis of its Phase III studies comparing millennial patients to non-millennials.

Peer-Reviewed Post Hoc Analysis Shows Jeuveau® is Highly Effective for Millennials by All Measures and at All Time Points Assessed

Here is how Evolus, Inc. (EOLS) and Computer Programs and Systems (CPSI) have performed compared to their sector so far this year.

Has Evolus (EOLS) Outpaced Other Medical Stocks This Year?

The average of price targets set by Wall Street analysts indicates a potential upside of 34.2% in Evolus, Inc. (EOLS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Predict a 34% Upside in Evolus, Inc. (EOLS): Here's What You Should Know

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus, Inc., today celebrates the three-year anniversary of the launch of its flagship neurotoxin product, Jeuveau® (prabotulinumtoxinA-xvfs).

Evolus Celebrates Third Anniversary of the Launch of Jeuveau® in the United States

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus announces that members of its management team will be participating in the H.C. Wainwright Global Investment Conference.

Evolus to Participate in the H.C. Wainwright Global Investment Conference

Evolus, Inc. (NASDAQ:EOLS ) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants David Erickson - Vice President-Investor Relations David Moatazedi - President and Chief Executive Officer Lauren Silvernail - Chief Financial Officer and Executive Vice President, Corporate Development Conference Call Participants Marc Goodman - SVB Leerink Douglas Tsao - H.C. Wainwright Operator Greetings, and welcome to the Evolus First Quarter 2022 Earnings Call.

Evolus, Inc. (EOLS) CEO David Moatazedi on Q1 2022 Results - Earnings Call Transcript

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus reports financial results for the first quarter ended March 31, 2022 and provides a business update.

Evolus Reports First Quarter 2022 Results and Provides Business Update

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus announces that it will report its first quarter 2022 financial results and provide a business update on Tuesday, May 10, 2022.

Evolus to Report First Quarter 2022 Results and Provide Business Update

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus enrolls its first patient in a clinical study evaluating an “extra-strength” dose for extended duration of Jeuveau® (prabotulinumtoxinA-xvfs).

Evolus Announces First Patient Enrolled in Phase II Clinical Study Evaluating “Extra-Strength” Dose of Jeuveau®

NEW YORK--(BUSINESS WIRE)-- #Class--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Evolus, Inc. (NASDAQ: EOLS) on behalf of long-term stockholders following a class action complaint that was filed against Evolus on October 16, 2020 with a Class Period from February 1, 2019 to July 6, 2020. Our investigation concerns whether the board of directors of Evolus have breached their fiduciary duties to the company. The complaint a

EVOLUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Evolus, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Small cap Evolus Inc. ( EOLS , Financial) is thinking big, and analysts agree the company can continue to make headway in the $2 billion U.S. market for aesthetics. The 10-year-old Newport Beach, California-based performance beauty company saw sales of its cosmetic neurotoxin Jeuveau jump 75% in 2021 to nearly $100 million.

Face It, Tiny Evolus Is Primed to Challenge AbbVie's Botox

Evolus' (EOLS) CEO David Moatazedi on Q4 2021 Results - Earnings Call Transcript

Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -45% and 0.12%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Evolus, Inc. (EOLS) Reports Q4 Loss, Misses Revenue Estimates

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus reports financial results for the fourth quarter and full-year ended December 31, 2021 and provides a business update.

Evolus Reports Fourth Quarter and Full-Year 2021 Results and Provides Business Update

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus announces that Lauren Silvernail will retire from her position as CFO and EVP of Corporate Development effective May 31, 2022.

Evolus Announces Retirement of Chief Financial Officer Lauren Silvernail

NEWPORT BEACH, Calif.--(BUSINESS WIRE)---- $EOLS--Evolus appoints Christos Monovoukas as Senior Vice President, Corporate Development, effective February 28, 2022.

Evolus Names Christos Monovoukas Senior Vice President of Corporate Development

Philadelphia, Pennsylvania--(Newsfile Corp. - February 28, 2022) - Kaskela Law LLC announces that it is investigating Evolus, Inc. ("Evolus" or the "Company") (NASDAQ: EOLS) on behalf of the Company's long-term stockholders. Recently an amended securities fraud complaint was filed against Evolus on behalf of certain investors who purchased shares of the Company's common stock between February 1, 2019 and July 6, 2020. According to the complaint, during that time period Evolus made a...

News for Evolus Stock (EOLS)